Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

New tumor imaging agent--/sup 111/In-bleomycin complex. Comparison with /sup 67/Ga-citrate and /sup 57/Co-bleomycin in tumor-bearing animals

Journal Article · · J. Surg. Oncol.; (United States)

A new /sup 111/In-bleomycin complex (BLMC) has been found which has high affinity to tumor, does not bind to transferrin and is stable in vivo. Distribution in animals bearing glioma, hepatoma, or mammary adenocarcinoma at 48 hours showed: the ratios of tumor to blood, brain, heart, lung, liver, pancreas, stomach, and femur were 1.4-22.4 times as high for /sup 111/In-BLMC as for /sup 67/Ga-citrate. In mammary adenocarcinoma, /sup 111/In-BLMC bound more to viable and /sup 57/Co-Bleomycin (BLM) more to necrotic tumor. In viable tumor, the concentration of /sup 111/In-BLMC was similar to that of /sup 57/Co-BLM. The ratios of tumor to stomach and pancreas were higher, to blood, brain, muscle, heart, and femur were lower for /sup 111/In-BLMC than those for /sup 57/Co-BLM. The ratios of tumor to lung, liver, spleen, skin, and kidney were similar for the two compounds. Tumors were imaged more distinctly with the new /sup 111/In-BLMC and /sup 57/Co-BLM than with /sup 67/Ga-citrate. /sup 111/In-BLMC is promising for tumor imaging.

Research Organization:
National Inst. of Health, Bethesda, MD
OSTI ID:
5969649
Journal Information:
J. Surg. Oncol.; (United States), Journal Name: J. Surg. Oncol.; (United States) Vol. 27:3; ISSN JSONA
Country of Publication:
United States
Language:
English